Home » EMA Awards Orphan Drug Designation to Loxo Oncology for LOXO-101
EMA Awards Orphan Drug Designation to Loxo Oncology for LOXO-101
January 22, 2016
The European Medicines Agency has blessed Loxo Oncology with orphan drug designation for LOXO-101, designed for the treatment of patients with soft tissue sarcoma.
LOXO-101 is being developed to treat patients with cancers containing abnormalities involving the tropomyosin receptor kinases.
Upcoming Events
-
21Oct